Premium
Emergent Biosolutions Inc (EBS)
NYSE
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | Ms. Sujata T. DayalIndependent Director | -13,76k | 115,61k | Automatic Disposition | 8,36 - 8,94 | 100,56k | -12,04% |
| 2026-04-30 | Mr. Keith A. KatkinIndependent Director | -15,48k | 128,18k | Automatic Disposition | 8,28 | 96,29k | -13,85% |
| 2026-05-01 | Mr. Donald W. DeGolyerIndependent Director | -15,48k | 129,99k | Automatic Disposition | 8,36 - 8,96 | 129,72k | -10,66% |
| 2026-05-01 | Dr. Kathryn C. ZoonIndependent Director | -17,20k | 144,45k | Automatic Disposition | 8,36 - 8,97 | 79,94k | -17,71% |
| 2026-04-01 | Mr. Paul A. WilliamsSVP of Products Business | -4,00k | 33,76k | Automatic Disposition | 8,44 | 62,68k | -6,00% |
| 2025-05-07 | Mr. Richard S. LindahlExec. VP & CFO | -40,28k | 0,00 | Other Derivative Disposition | 48,33 - 61,01 | 0,00 | -100,00% |
| 2026-03-05 | Mr. Joseph C. PapaCEO, President & Director | -37,06k | 312,74k | Sale to Issuer | 8,44 | 305,45k | -10,82% |
| 2026-03-05 | Mr. Simon C. LowryChief Medical Officer and Head of Research & Development | -10,64k | 89,77k | Sale to Issuer | 8,44 | 16,48k | -39,22% |
| 2026-03-05 | Ms. Jessica PerlSenior VP, Corporate Secretary & General Counsel | -6,47k | 54,56k | Sale to Issuer | 8,44 | 61,00k | -9,58% |
| 2026-03-05 | Mr. William HartzelSVP of Manufacturing & Bioservices | -9,49k | 80,12k | Sale to Issuer | 8,44 | 87,19k | -9,82% |
| 2026-03-05 | Mr. Paul A. WilliamsSVP of Products Business | -9,40k | 79,31k | Sale to Issuer | 8,44 | 66,68k | -12,35% |
| 2026-03-05 | Mr. Richard S. LindahlExec. VP & CFO | -23,65k | 199,61k | Sale to Issuer | 8,44 | 215,37k | -9,89% |
| 2026-03-05 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -8,20k | 69,20k | Sale to Issuer | 8,44 | 104,11k | -7,30% |
| 2026-03-01 | Mr. Paul A. WilliamsSVP of Products Business | -116,00 | 945,40 | Sale to Issuer | 8,15 | 76,08k | -0,15% |
| 2026-03-01 | Mr. Richard S. LindahlExec. VP & CFO | -683,00 | 5,57k | Sale to Issuer | 8,15 | 239,02k | -0,28% |
| 2026-03-01 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -313,00 | 2,55k | Sale to Issuer | 8,15 | 112,31k | -0,28% |
| 2026-02-09 | Ms. Jessica PerlSenior VP, Corporate Secretary & General Counsel | -918,00 | 10,13k | Sale to Issuer | 11,03 | 67,47k | -1,34% |
| 2026-02-06 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -31,70k | 346,15k | Sale to Issuer | 10,92 | 112,62k | -21,96% |
| 2026-02-06 | Mr. William HartzelSVP of Manufacturing & Bioservices | -6,40k | 69,90k | Sale to Issuer | 10,92 | 96,68k | -6,21% |
| 2026-02-06 | Mr. Paul A. WilliamsSVP of Products Business | -9,68k | 105,67k | Sale to Issuer | 10,92 | 76,19k | -11,27% |
| 2026-02-06 | Mr. Richard S. LindahlExec. VP & CFO | -51,80k | 565,62k | Sale to Issuer | 10,92 | 239,70k | -17,77% |
| 2025-12-14 | Mr. Simon C. LowryChief Medical Officer and Head of Research & Development | -3,54k | 40,43k | Sale to Issuer | 11,41 | 6,28k | -36,05% |
| 2025-12-05 | Mr. Ronald B. RichardInitié | -25,75k | 177,09k | Derivative Exercise and Sale | 5,02 - 11,90 | 64,01k | - |
| 2025-12-05 | Mr. Ronald B. RichardInitié | -7,10k | 85,99k | Vente | 12,11 | 64,01k | -9,98% |
| 2025-11-11 | Mr. William HartzelSVP of Manufacturing & Bioservices | -610,00 | 6,64k | Sale to Issuer | 10,88 | 103,08k | -0,59% |
| 2025-11-10 | Mr. Donald W. DeGolyerIndependent Director | -17,80k | 187,62k | Automatic Disposition | 10,54 | 45,90k | -27,95% |
| 2025-11-07 | Ms. Sujata T. DayalIndependent Director | -8,55k | 85,52k | Automatic Disposition | 10,00 | 54,58k | -13,55% |
| 2025-10-15 | Mr. Richard S. LindahlExec. VP & CFO | -5,00k | 47,95k | Sale to Issuer | 9,60 | 291,50k | -1,68% |
| 2025-08-15 | Dr. Kathryn C. ZoonIndependent Director | -7,09k | 62,85k | Automatic Disposition | 8,87 | 37,40k | -15,93% |
| 2025-08-12 | Mr. Donald W. DeGolyerIndependent Director | -7,84k | 67,83k | Vente | 8,65 | 24,14k | -24,52% |
| 2025-07-11 | Mr. William HartzelSVP of Manufacturing & Bioservices | -4,26k | 31,38k | Sale to Issuer | 7,36 | 103,69k | -3,95% |
| 2025-06-08 | Ms. Coleen GlessnerExec. VP of Quality, Ethics & Compliance | -1,25k | 8,28k | Sale to Issuer | 6,63 | 174,93k | -0,71% |
| 2025-06-08 | Mr. William HartzelSVP of Manufacturing & Bioservices | -1,17k | 7,74k | Sale to Issuer | 6,63 | 107,96k | -1,07% |
| 2025-06-08 | Mr. Paul A. WilliamsSVP of Products Business | -464,00 | 3,08k | Sale to Issuer | 6,63 | 85,87k | -0,54% |
| 2025-06-08 | Mr. Richard S. LindahlExec. VP & CFO | -2,73k | 18,12k | Sale to Issuer | 6,63 | 296,49k | -0,91% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
